Grant of Stock Acquisition Rights to Directors
First written in FY2021-Q1. 3 of 7 entries say "Restated". Latest entry: FY2025.
- FY2025RaisedAnnual report
「The number of stock acquisition rights is capped at 3,240.” “Capped at 324,000 common shares of the company.” “From the first day of the month following the month containing the date two years after the date of the resolution granting the stock acquisition rights to 26 June 2035」
Under the resolution of the 26 June 2025 General Meeting of Shareholders, the issuance limit for stock acquisition rights for directors, subsidiary directors and employees was increased to 3,240 rights, underlying 324,000 common shares. The exercise period was set to end on 26 June 2035. - FY2024AdvancedAnnual report
「Capped at 263,000 common shares of the company.” “Exercise period for the stock acquisition rights From the first day of the month following the month containing the date two years after the date of the resolution granting the stock acquisition rights to 27 June 2034」
Under the resolution of the 27 June 2024 General Meeting of Shareholders, a framework was established to issue up to 2,630 stock acquisition rights underlying 263,000 common shares to directors, subsidiary directors and employees. - FY2022RestatedAnnual report
「Granted - 7,500 Vested - - Unvested balance 39,000 202,000」
The 2021 stock options for directors and employees were disclosed as an unvested balance of 202,000 shares after 7,500 shares expired. - FY2022-Q3RestatedAnnual report
「To strengthen staffing for the medical-related business, we have introduced stock options and performance-linked bonus schemes. Stock-based compensation expense of ¥62 million for the nine-month period ended December, including ¥29 million for the three-month period, was recognized in selling, general and administrative expenses in connection with the issuance of tax-qualified stock options.」
The introduction and operation of stock options to strengthen staffing in the medical-related business continued, and stock-based compensation expense of ¥62 million was recognized. - FY2022-Q1RestatedAnnual report
「Resolution date: 29 June 2021; categories and numbers of eligible persons (people): 2 directors of the company; 3 directors of the subsidiary グローム・マネジメント株式会社; 11 employees of the company; 38 employees of the subsidiary グローム・マネジメント株式会社; number of stock acquisition rights: 2,095; class, terms and number of shares underlying the stock acquisition rights: common shares, 209,500 shares; exercise price per share: ¥1,710; exercise period: from 1 July 2023 to 28 June 2031」
The terms of the 2,095 stock acquisition rights underlying 209,500 shares for directors and employees are reiterated, with an exercise price of ¥1,710 and an exercise period from 1 July 2023 to 28 June 2031. - FY2021RaisedAnnual report
「Categories and numbers of eligible persons (people): 2 directors of the company; 3 directors of the subsidiary グローム・マネジメント株式会社; 11 employees of the company; 38 employees of the subsidiary グローム・マネジメント株式会社; number of stock acquisition rights: 2,095; class, terms and number of shares underlying the stock acquisition rights: common shares, 209,500 shares」
The eligible recipients were expanded from directors only under the previous stock acquisition rights to include employees, and the issuance of 5th Series stock acquisition rights underlying 209,500 shares was approved. - FY2021-Q1First statedAnnual report
「Resolution date: 26 June 2020; categories and numbers of eligible persons (people): 3 directors of the company; 3 directors of the subsidiary グローム・マネジメント株式会社; number of stock acquisition rights: 390; class, terms and number of shares underlying the stock acquisition rights: common shares, 39,000 shares; exercise price per share: ¥1,040; exercise period: from 1 July 2022 to 25 June 2030」
A total of 6 directors of the company and its subsidiary were granted 390 stock acquisition rights underlying 39,000 common shares. The exercise price is ¥1,040, and the exercise period is from 1 July 2022 to 25 June 2030.